UltraShape Is Recognized As A Breakthrough In Non-Invasive Abdominal Fat Reduction Thanks To Its Painless And Effective Ultrasound Technology
WAYLAND, Mass., Jan. 15, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that NewBeauty Magazine awarded UltraShape® the "Best Body-Contouring Treatment" in its annual 2014 Beauty Choice Awards. As a winner in the coveted "Beauty Game Changers" category, UltraShape is recognized for its innovative ultrasound-based treatment that painlessly and permanently destroys fat in the abdominal area where fat is most resistant to diet and exercise.
Featured alongside an elite list of outstanding aesthetic products, NewBeauty notes that UltraShape was chosen by a panel of thousands of readers, editors and beauty industry experts for its ability to deliver real, noticeable and highly customizable results "without surgery or hours spent in the gym."
"As the number of satisfied UltraShape users continues to grow, we are honored to earn recognition from NewBeauty Magazine, further validating our leading position in the body shaping space," said Dr. Shimon Eckhouse, Chairman of the Board of Directors for Syneron. "UltraShape represents the next generation in body-shaping with proven clinical outcomes and a superior safety profile, underscoring Syneron's ongoing commitment to advancing treatment outcomes through technological innovation."
"What sets UltraShape apart from other body shaping solutions is its fast outcomes with results visible in often as little as 2 weeks post first treatment," says Amit Meridor, Chief Executive Officer of Syneron. "With UltraShape's customizable treatments, for the very first time physicians are able to truly sculpt instead of bulk heat or freeze fat. UltraShape is a painless solution for those who cannot get rid of stubborn fat resistant to diet and exercise."
The UltraShape System is the first and only non-invasive body shaping treatment that uses pulsed focused ultrasound energy to precisely target subcutaneous fat, while keeping the surrounding tissue, vasculature, nerves and muscles intact. Unlike other body shaping technologies that use heat or freezing techniques, UltraShape uses a pure mechanical effect to destroy fat cells without inducing thermal damage. This unique feature of UltraShape technology results in a safe and comfortable treatment experience with no visible signs of treatment and no downtime.
The newest fat-blasting treatment on the block, UltraShape, with over 300,000 procedures performed worldwide, was cleared by the United States Food and Drug Administration (FDA) 510(k) for non-invasive reduction of abdominal circumference via fat cell destruction in April of last year.
NewBeauty® magazine is the definitive authority on all things beauty. Each issue of NewBeauty gives readers an in-depth look at the beauty industry's latest products, cutting-edge innovations and breakthrough technologies. Whether it's the latest high-powered skin care or in-office procedure, NewBeauty educates readers on the latest options for skin, face, hair, body, well-being and smile. The magazine's comprehensive approach to its topics continues to solidify its reputation as the industry's leading scientifically accurate, expert-driven and ethically balanced beauty resource.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Additional information can be found at www.syneron-candela.com
KELZ PR - 646-450-5359
Patty Mathews – email@example.com
Melissa Ben-Yoseph - Melissa@kelzpr.com
Zack Kubow, The Ruth Group firstname.lastname@example.org, 646-536-7020
Hugo Goldman, Chief Financial Officer, Syneron Hugo.Goldman@syneron.com
Syneron Medical Public Relations email@example.com
Photo - http://photos.prnewswire.com/prnh/20150115/169395
Logo - http://photos.prnewswire.com/prnh/20120528/535447
SOURCE Syneron Medical Ltd.